Molly has made over 4 trades of the Amedisys stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,537 units of AMED stock worth $148,659 on 19 May 2017.
The largest trade he's ever made was exercising 1,537 units of Amedisys stock on 19 May 2017 worth over $148,659. On average, Molly trades about 369 units every 16 days since 2016. As of 19 May 2017 he still owns at least 8,174 units of Amedisys stock.
You can see the complete history of Molly Coye stock trades at the bottom of the page.
Dr. Molly J. Coye M.D. serves as Independent Director of the Company. She has served as Senior Advisor and Executive in Residence for AVIA, a membership network of healthcare delivery systems that provides strategic and technology selection advice regarding digital health software and devices and is the nation’s leading healthcare innovation network, since 2015. She also served as an Innovation Advisor for Evolent Health from 2018 to 2019. From 2010 to 2015, Dr. Coye was Chief Innovation Officer of the UCLA Health System (comprehensive health care organization). Dr. Coye served on the Board of Directors of Aetna, Inc. from 2005 to 2018, where she was a member of the Executive Committee, the Committee on Investment and Finance, Chair of the Committee on Medical Affairs, and a member of the board of the Aetna Foundation. She previously served as Commissioner of Health for the State of New Jersey, Director of the California State Department of Health Services, Head of the Division of Public Health Practice at the Johns Hopkins School of Hygiene and Public Health, chair of the board of PATH and the American Public Health Association, and on the boards of the American Hospital Association, the American Telemedicine Association, The California Endowment, and the China Medical Board.
As the Independent Director of Amedisys, the total compensation of Molly Coye at Amedisys is $142,302. There are 15 executives at Amedisys getting paid more, with Paul Kusserow having the highest compensation of $12,835,500.
Molly Coye is 72, he's been the Independent Director of Amedisys since 2019. There are no older and 20 younger executives at Amedisys.
Molly's mailing address filed with the SEC is 3854 AMERICAN WAY, SUITE A, , BATON ROUGE, LA, 70816.
Over the last 27 years, insiders at Amedisys have traded over $269,564,877 worth of Amedisys stock and bought 2,690,968 units worth $38,198,016 . The most active insiders traders include Asset Management Llc Kohlbe..., Tide Capital, Llc North Tid..., and David Nierenberg. On average, Amedisys executives and independent directors trade stock every 29 days with the average trade being worth of $2,494,602. The most recent stock trade was executed by Richard M Ashworth on 26 December 2023, trading 11,237 units of AMED stock currently worth $896,937.
amedisys is a leading provider of healthcare in the home with a vision of becoming the premiere solution for patients across the country to age in place. from home health to hospice to personal care, amedisys team members provide quality, clinically-distinctive care to more than 376,000 patients every year. every life is precious and tells an incredible story, and we celebrate that each day by honoring our patients with genuine, personal attention. everything we do, from the boardroom to our nationwide network of care centers, is centered on the best care possible for those who have entrusted us with their well-being and comfort. we work closely with doctors and other healthcare providers to coordinate services, and every patient has an individual plan of care that meets their specific needs. amedisys recognizes that nothing we do is possible without our incredible team. for all employees, whether they’re on the front lines delivering direct care or supporting our clinical team, this i
Amedisys executives and other stock owners filed with the SEC include: